BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20683952)

  • 1. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway.
    Wang XQ; Ongkeko WM; Chen L; Yang ZF; Lu P; Chen KK; Lopez JP; Poon RT; Fan ST
    Hepatology; 2010 Aug; 52(2):528-39. PubMed ID: 20683952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
    Jia Q; Zhang X; Deng T; Gao J
    Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling.
    Hu C; Li H; Li J; Zhu Z; Yin S; Hao X; Yao M; Zheng S; Gu J
    Carcinogenesis; 2008 Dec; 29(12):2289-97. PubMed ID: 18820285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
    Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
    Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
    Hou H; Sun H; Lu P; Ge C; Zhang L; Li H; Zhao F; Tian H; Zhang L; Chen T; Yao M; Li J
    Mol Cancer Ther; 2013 Dec; 12(12):2874-84. PubMed ID: 24130050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenite inhibits the function of CD133
    Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
    Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
    Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
    J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumorspheres Derived from HCC Cells are Enriched with Cancer Stem Cell-like Cells and Present High Chemoresistance Dependent on the Akt Pathway.
    Zhang XL; Jia Q; Lv L; Deng T; Gao J
    Anticancer Agents Med Chem; 2015; 15(6):755-63. PubMed ID: 25642979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
    Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
    Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
    Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
    Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation.
    Lee TK; Castilho A; Cheung VC; Tang KH; Ma S; Ng IO
    Hepatology; 2011 Jan; 53(1):160-70. PubMed ID: 20979057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways.
    Chen Q; Li W; Wan Y; Xia X; Wu Q; Chen Y; Lai Z; Yu C; Li W
    Hepatology; 2012 Jun; 55(6):1820-9. PubMed ID: 22213475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma.
    Park SY; Han J; Kim JB; Yang MG; Kim YJ; Lim HJ; An SY; Kim JH
    Eur J Cancer; 2014 Jan; 50(2):341-50. PubMed ID: 24161763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway.
    Wang Z; Wang N; Li W; Liu P; Chen Q; Situ H; Zhong S; Guo L; Lin Y; Shen J; Chen J
    Carcinogenesis; 2014 Oct; 35(10):2346-56. PubMed ID: 25085904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells.
    Zhu P; Wang Y; He L; Huang G; Du Y; Zhang G; Yan X; Xia P; Ye B; Wang S; Hao L; Wu J; Fan Z
    J Clin Invest; 2015 Oct; 125(10):3795-808. PubMed ID: 26426078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
    Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
    Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing survivin.
    Fan L; Sun G; Ma T; Zhong F; Lei Y; Li X; Wei W
    J Pineal Res; 2013 Sep; 55(2):184-94. PubMed ID: 23711089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.